Author: Shernide Delva
A few weeks ago, my sister told me about an upcoming concert that would celebrate popular acts such as DMX and several others. The event was called the “Ruff Ryders and Friends – Reunion Tour – Past, Present and Future” and would be in Miami on September 7th.
Tickets were cheap so I figured why not. I opened my computer and prepared to purchase the tickets for the show until I read the letters in red: “Canceled.” This was certainly not what I had hoped for.
Why did the show get canceled?
In fact, why did the entire tour get canceled? I could not believe my eyes as I glanced over the list of cancellations. Cancelling an entire tour is practically unheard of. What happened? Sadly, the answer involves drug addiction.
After some careful searching, I discovered a TMZ article which reported back in April that DMX had to cancel his shows due to an “unspecified medical issue.” Sources at a Los Angeles show state the rapper had been drinking heavily.
His history with substance abuse is not anything surprising. In the past, the rapper was open about his journey to addiction recovery. Therefore, when news of his drinking spread, relapse concerns heightened.
It turns out DMX has reportedly sought treatment for drug addiction. Addiction treatment reports surfaced a couple weeks after the rapper was put on house arrest for violating bail conditions.
According to speculations, the 46-year old is undergoing treatment in the Nashua, New Hampshire area or is living in a sober home. The Nashua Telegraph reported that DMX, whose real name is Earl Simmons, was spotted at a local Buffalo Wild Wings, a Shaw’s supermarket, and a Walmart.
Along with addiction troubles, Simmons is facing charges that he allegedly owes $1.7 million in back taxes dating back to 2000. He has pleaded not guilty to these charges and was freed on $500,000 bail, according to Billboard. Still, while he was on bail, the rapper failed drug test four times. These test found cocaine, opiates, and pot in his system. Because of these results, Manhattan Federal Judge Jed Rakoff put him under house confinement on August 11.
During the hearing, the judge stated that Simmons had violated bail “probably more times than I can remember,” according to Court House News. He chose not to send the rapper to jail, although he described Simmons’s drug addiction as “gross.” He said that his past run-ins with the law exemplified that he’s had “more than a passing acquaintance with illegal drugs.”
After that hearing, DMX told a reporter, “When God is for you, who can be against you?”
The judge reportedly lifted Simmons’s house arrest on the condition that he enter a sober program and travel with a sober coach around the clock. According to court documents reviewed by TMZ, the rapper would need permission to leave New York State.
According to his lawyer Murray Richman, the rapper has decided to go to rehab on his own.
“This is a voluntary move on his part,” Richman said.
It is clear that DMX has struggled on and off with drug addiction. We wish him the best as he seeks a life free from the grips of substance abuse. Recovery is possible, and it is the answer out of this cycle. If you are struggling with drugs or alcohol dependency, please call now. We are here to help. Do not wait.
CALL NOW 1-800-951-6135
Author: Shernide Delva
In the past, we’ve talked about the potential of opioid vaccines. These vaccines could have a major impact on lowering a number of opioid overdose deaths. They could completely shift the direction of how we treat opioid addiction. However, is the future of opioids imminent or far, far away?
Sadly, it will be a long time before we see opioid vaccines available for widespread use. Experts all agree that although the future of opioid vaccines looks bright, the process of getting a drug into the market is a lengthy one and we should not hold our breath just yet.
Recently, Health and Human Services Secretary Tom Price mentioned opioid vaccines as an exciting new development in the war against opioid abuse.
“One of the exciting things that they’re actually working on is a vaccine for addiction, which is incredibly exciting,” Price said during a briefing about the drug epidemic.
However, experts say it won’t be made public for years… if ever.
The process of a drug going from the research phase to the production phase is a long, tedious process. Opioid addiction vaccines have not even begun human trials yet. Researchers would have to put drugs through phase one, two and three trials before submitting them for approval by the Food and Drug Administration (FDA), given that the trials are successful.
“He may be a physician, but he’s not terribly well-informed about addictions,” said Dr. Thomas R. Kosten, a psychiatry professor at the Baylor College of Medicine with a concentration in addiction vaccines. “I can’t imagine the vaccine would be on the market before the Trump administration is over.”
Dr. Kosten knows all about vaccines. He worked on cocaine vaccines for 16 years before deciding that it “just didn’t work well enough” to continue. Today, he is working on a vaccine for fentanyl, an opioid painkiller up to 100 times stronger than morphine. Fentanyl has been a major culprit for overdose deaths in the current opioid epidemic.
Those who previously used painkillers turn to heroin due to the lower price and easier access. Unfortunately, often heroin is not just heroin and instead is laced with powerful painkillers like fentanyl which make a user much more susceptible to an overdose.
Dr. Kosten hopes his work on the vaccine will pan out, but he wants to ensure people are not holding their breath. These things take time.
“There are no opiate vaccines that have been in people at this point,” said Dr. Kosten.
Even if the vaccine passes trials and goes into full-scale production, it would only be used therapeutically, not as a preventative measure.
“The purpose is not to “mass-immunize a whole bunch of kids,” Dr. Kosten said. “That’s not at all what they’re designed for.”
For now, the vaccine is proving to be effective in animal testing. However, this is not necessarily good news.
“Sometimes, the translation from animals is not necessarily the same in humans. So we have to do the human studies,” said Dr. Ivan Montoya of NIDA’s Division of Therapeutics and Medical Consequences.
The goal of the vaccine is to allow the body’s own immune system to combat opioids before they can reach the brain and take effect.
“We don’t have to modify the brain to produce the effect,” said Dr. Montoya. “You take advantage of your own immune system and prevent access of the drug to the brain.”
In the future, Dr. Montoya hopes to come up with a vaccine that can block the effects of a wide range of opioids including fentanyl, heroin, and OxyContin.
While the prospect of opioid vaccines sounds promising, we are still far away from this becoming a reality. Therefore, stating vaccines as an exciting solution to the opioid epidemic is a bit of a stretch for now. Instead, the focus should be placed on increasing access to treatment. With the right program, recovery is possible. If you are struggling with substance abuse, call now. Do not wait.
CALL NOW 1-800-951-6135
Author: Shernide Delva
Each year, more than 300 million people are affected by depression. Depression is a debilitating illness that is difficult to treat.
What if there was one gene that played a key role in depression? Furthermore, what if that gene could be identified and even manipulated to actually treat depression?
Shockingly, this could all be a possibility. Researchers have discovered a gene that may play a central role in depression. This gene either protects us from stress or triggers a downward spiral depending on its level of activity.
The study was conducted by researchers at the University of Maryland School of Medicine (UM SOM). It was the first to pinpoint in detail how one particular gene, known as Slc6a15, is a key role in depression. The study found the same link in both animals and humans.
“This study really shines a light on how levels of this gene in these neurons affects mood,” said the senior author of the study, Mary Kay Lobo, an assistant professor in the Department of Anatomy and Neurobiology.
“It suggests that people with altered levels of this gene in certain brain regions may have a much higher risk for depression and other emotional disorders related to stress.”
Potential Treatment Solution?
A study like this could help with treating depression in the future, and that help is desperately needed.
Nearly 800,000 people die annually from suicide. It is the second leading cause of death among people between the ages of 15 to 29. Beyond that, depression destroys the quality of life for tens of millions of patients, and their families suffer too. Although environmental factors play a significant role in many cases of depression, genetics are equally as important.
This is not the first time this gene was studied. Back in 2006, Dr. Lobo and her colleagues found that the Slc6a15 gene was common in specific neurons in the brain. They recently demonstrated that these neurons were important in depression.
Connection to Anhedonia
Her lab decided to investigate the specific role these neurons have in depression. In the latest study, she and her team focused on a particular area of the brain called the nucleus accumbens. This region is crucial in the brain’s “reward circuit.”
When you eat a delicious meal or participate in any kind of enjoyable experience, neurons in the nucleus accumbens are activated letting you know the experience is enjoyable. When a person is depressed, it ‘s hard to experience any kind of enjoyment, a condition known as anhedonia.
Researchers discovered subset neurons in the nucleus accumbens called D2 neurons. These neurons respond to the neurotransmitter dopamine, which plays a central role in the reward circuit.
Mainly, these subset neurons responded to feel good chemicals like dopamine which is lacking in those with depression. Next, they studied mice susceptible to depression. These mice tended to withdraw from activities and exhibit behavior indicating depression such as social withdrawal and lack of interest in the food they would normally enjoy.
Dr. Lobo found that when the mice were subject to social stress, the levels of the Slc6a15 gene in the D2 neurons of the nucleus accumbens was noticeably reduced. The researchers also studied mice in which the gene had been reduced in D2 neurons. When those mice were subjected to stress, they also exhibited signs of depression. Furthermore, when researchers increased the levels of Slc6a15 levels in D2 neurons, the mice showed a resilient response to stress.
So what does this mean?
Next, Dr. Lobo looked at brains of humans who had a history of major depression and who had committed suicide. In the same region of the brain as the mice, the gene Slc6a15 was reduced. This indicates that the link between gene and behavior is found in both humans and mice.
In the future, manipulating these genes could help improve depression. While it is still unclear how Slc6a15 operates in the brain, Dr. Lobo states it may work by altering neurotransmitter levels in the brain.
This research could lead to therapies that focus specifically on this particular gene to treat depression. If you are struggling with substance abuse or mental illness, call now. Do not wait.
CALL NOW 1-800-951-6135
Author: Shernide Delva
In the past, we’ve talked about the effects opioids have had on the workforce. We’ve analyzed issues such as how employers handle addiction and how to take time off to seek treatment.
However, a recent article delved further into the complications opioid use have on the workforce.
What if I told you that fewer people were looking for a job or had a job because of opioid addiction?
It turns out, this is a real possibility.
Workforce participation is defined as the number of people working or actively looking for work. Workforce participation has decreased significantly, despite increases in job creation and decreases in unemployment.
One economist points out this decrease may be due to an unlikely cause: opioid addiction.
“Use of both legal prescription pain relievers and illegal drugs is part of the story of declining prime-age participation, especially for men, and this reinforces our doubts about a rebound in the participation rate,” said David Mericle, senior U.S. economist at Goldman Sachs, who prepared a report on the issue earlier this week.
This belief is contrary to recent CBS reports which noted that the decline in workplace participation was due to less demand for lower skilled workers and rising disability rates.
On the contrary, David Mericle argues the reduction in workplace participation has more to do with opioid abuse.
“Data on substance abuse treatment episodes also reinforce the narrative: Of admissions of individuals not in the labor force, 58% described themselves as being out of the labor force for ‘other’ reasons—meaning they aren’t students, disabled, retired, inmates or homemakers—and 47% of these admissions were for opioids, well above the average rate,” he wrote in the report.
This issue simply cannot be ignored.
The opioid crisis has a clear impact on workplace participation because those who struggle with opioid addiction may quit their jobs or get fired. Then, those same people will not apply for other jobs due to their concerns regarding their ability to meet the demands of the work or even pass a drug screening.
“Especially in companies that hire drivers, we hear a lot about how the drug tests are a problem there,” Gad Levanon, chief economist for North America of The Conference Board told CBS. “Many of [the applicants] don’t pass it, so they can’t hire them—and they don’t know many aren’t even trying.”
Opioid abuse is rampant in the same demographic that has seen the largest decline in workforce participation. Opioid use is prevalent in rural areas which commonly struggle economically. A report stated that 22 out of 25 most impacted by opioid abuse are in rural areas or the South.
Which Came First: Economic Hardships or Opioid Abuse?
Mericle did not elaborate on how economic hardships may have influenced opioid abuse in these rural areas or vice versa. He concluded that the opioid epidemic “is intertwined with the story of declining prime-age participation, especially for men.” Essentially, it is hard to determine what led to what.
What do you think? Should we blame the decrease in workforce participation on opioid abuse or do other factors play a more significant role? Regardless of the effect opioids have on the workforce, the reality remains that it is a serious problem.
People who struggle with addiction often quit their jobs, or refuse to look at all because of their addiction. Therefore, a push for treatment is critical. If you are struggling with substance abuse or mental illness, call now. Do not wait.
CALL NOW 1-800-951-6135
Author: Shernide Delva
The United States has slowly begun to see more and more states approve medical and even recreational marijuana. But the U.S. is far from the only country seeing major shifts in marijuana policies.
Greece just joined six other European Union countries in approving some form of medical cannabis. Greece is “turning its page” on drug policy by allowing qualified citizens to access medical cannabis. The announcement by Greek officials occurred on June 30 at a press conference.
“Greece is now included in countries where the delivery of medical cannabis to patients in need is legal,” according to Greece’s Government Gazette.
Now that the government had reclassified cannabis from Table A to Table B, it is now possible for certain patients to access marijuana for medical purposes legally. This move is like moving cannabis from Schedule I to Schedule II of the United States’ Controlled Substances Act.
In the U.S., cannabis is still classified under Schedule I, alongside heroin and LSD. Although various states permit marijuana use, it is still not legal on a federal level. Drugs like oxycodone, methadone, and methamphetamine are in Schedule II, a less restrictive drug category.
With these new implementations, Greece can now import products from other countries like Canada and the United States. There are qualifying conditions required by the Ministry of Health that patients must have to access medical marijuana.
These health conditions include:
- Chronic or Neuropathic Pain
- Nausea & vomiting from chemotherapy
- Some eating disorders
“From now on, the country is turning its page, as Greece is now included in countries where the delivery of medical cannabis to patients in need is legal,” said Greek Prime Minister Alexis Tsipras.
Greece joins six other European Union countries that have approved medical cannabis in some form.
Other countries include:
- The Czech Republic
- The Netherlands
Germany is a recent addition to the list. Their law went into effect this past March to help “critically ill” citizens.
Another country approving cannabis in June is Mexico, where the new law passed legislation with overwhelming support.
A country like Greece supporting medical marijuana is a major shift in the country’s mentality. Greece has a long known history of strict anti-drug laws. However, the debt-ridden country is moving in a different direction. The government legalized the processing of hemp in April, “ending 60 years of prohibition of the traditional, non-psychoactive plant,” Leafly reported at the time.
Hemp is a variety of the Cannabis sativa plant species that is grown specifically for mass use. Although hemp and marijuana come from the same plant, they are distinctively different. Hemp has low THC levels, which means it does not produce a high. Hemp is processed into a variety of useful products including paper, textiles, clothing, plastics, biofuel, and food.
Marijuana reform remains a controversial topic. However as the medical benefits of cannabis continue to reveal themselves, more countries are opening up to the idea of legalization. What do you think about the recent legalization of medical marijuana in Greece?
Like any substance, marijuana can be abused. If you are struggling with substance abuse or addiction, please seek help. Regardless of whether a drug is legalized or not, if you feel out of control with your substance use, please reach out. We want to help.
CALL NOW 1-800-951-6135